|
Peter Thornton is senior vice president of technology, business and product development at Elan Drug Technologies, where he coordinates R&D and business development activities across all of EDT’s sites. Previously, he was president and chief operating officer at Circ Pharma Limited, a specialty pharmaceutical product development company with a late-stage pipeline of novel formulations of existing drugs in the areas of cardiology and neurology. In 2004, Mr. Thornton joined Antigenics as chief financial officer from the global biopharmaceutical company Elan Corporation, plc., where he held senior management positions in operations and finance. He was latterly Elan’s senior vice president of business operations, focusing on the operational management of several business units, and restructuring and divestiture activities. During Mr. Thornton’s tenure at Elan, he also served as senior vice president of finance and operations for Elan’s drug delivery division. Prior to joining Elan in 1994, Mr. Thornton worked at the international accounting firm KPMG in Dublin and Paris. Mr. Thornton is a nonexecutive director of specialty pharmaceutical companies, Cydex Inc. and Merrion Pharmaceuticals Limited. Mr. Thornton earned his bachelor’s degree in commerce from University College, Cork, Ireland, and is a fellow of the Institute of Chartered Accountants in Ireland. | 